Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.
Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan,
Oncology. 2020;98(4):230-236. doi: 10.1159/000505128. Epub 2020 Jan 21.
Synchronous colorectal peritoneal carcinomatosis (SCPC) is not a rare entity, and the prognosis is extremely poor compared to other metastatic sites such as the liver and lung. Therefore, optimal treatment based on tumor characteristics is needed. Recently, the tumor sidedness of colorectal cancer has been reported as one of the prognostic factors and also as a key factor for the treatment strategy. The purpose of this study was to assess the clinical impact of tumor sidedness in patients with SCPC.
A total of 189 cases of SCPC were identified in a retrospective database at Wakayama Medical University Hospital (WMUH) between 1998 and 2014, and were analyzed with a special focus on tumor location.
In multivariate analysis, a right-sided location (p = 0.02) and the presence of liver metastases (p < 0.001) were found to be the worst prognostic factors. The median survival time (MST) with right-sided and with left-sided SCPC was 10 and 16 months, respectively. The right-sided SCPC group included more aged patients (p = 0.045) and fewer patients who received postoperative chemotherapy (p = 0.034). When we focused on patients with macroscopically complete resection (n = 39), the MST and disease-free survival in the right-sided SCPC group was significantly shorter than in the left-sided SCPC group (p = 0.030 and p = 0.043, respectively). The MST of the right-sided and the left-sided SCPC patients among the completely resected patients was 24 and 73 months, respectively.
Tumor sidedness may be a potent prognostic indicator for patients with SCPC. The survival time with right-sided SCPC is dramatically reduced compared to that with left-sided SCPC, especially among completely resected cases. We should change the treatment strategy according to the location of SCPC.
同步结直肠腹膜癌转移(SCPC)并不罕见,与肝、肺等其他转移部位相比,预后极差。因此,需要根据肿瘤特征进行最佳治疗。最近,结直肠癌的肿瘤侧别已被报道为预后因素之一,也是治疗策略的关键因素。本研究旨在评估 SCPC 患者肿瘤侧别的临床影响。
回顾性分析和歌山医科大学医院(WMUH)1998 年至 2014 年期间的数据库中,共确定了 189 例 SCPC 病例,并特别关注肿瘤位置进行分析。
多因素分析发现,右侧肿瘤位置(p = 0.02)和肝转移存在(p < 0.001)是最差的预后因素。右侧和左侧 SCPC 的中位生存时间(MST)分别为 10 个月和 16 个月。右侧 SCPC 组包括更多年龄较大的患者(p = 0.045)和较少接受术后化疗的患者(p = 0.034)。当我们专注于宏观完全切除的患者(n = 39)时,右侧 SCPC 组的 MST 和无病生存率明显短于左侧 SCPC 组(p = 0.030 和 p = 0.043)。完全切除患者中右侧和左侧 SCPC 患者的 MST 分别为 24 个月和 73 个月。
肿瘤侧别可能是 SCPC 患者的一个有力预后指标。与左侧 SCPC 相比,右侧 SCPC 的生存时间明显缩短,尤其是在完全切除的病例中。我们应根据 SCPC 的位置改变治疗策略。